Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Viehbacher assessing BD as Biogen ‘rebalances’ risk, reward in pipeline

With launches looming and chairman likely to retire, new CEO eyes shorter timelines to proof of concept, will mull bringing in assets via deals

February 15, 2023 8:31 PM UTC

As new CEO Christopher Viehbacher seeks to rebalance risk and potential reward in Biogen’s pipeline, the company could look to deals for innovative products that will help drive its return to growth.

During the company’s 4Q22 and full-year earnings call Wednesday, Viehbacher said Biogen Inc. (NASDAQ:BIIB) could further explore “external growth opportunities” in immunology, rare diseases or psychiatry. The company is looking to hire a head of business development, as well as a head of research; it has split its top R&D role in two positions, with Priya Singhal now serving as head of development...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Biogen Inc.

BCIQ Target Profiles

Superoxide dismutase 1 (SOD1)